Updates are available Correction dated 2021-06-25
Click to view Correction: https://doi.org/10.1007/s00262-021-02977-6
-
Authors
Teck, Anja Tatjana https://orcid.org/0000-0002-9563-0341
Urban, Sabrina
Quass, Petra
Nelde, Annika
Schuster, Heiko
Letsch, Anne
Busse, Antonia
Walz, Juliane Sarah
Keilholz, Ulrich
Ochsenreither, Sebastian
-
Funding
Funding for this research was provided by:
Berliner Krebsgesellschaft (OCFF201516)
Deutsche Krebshilfe (70111580)
- License Information
-
More Information
Article History
Received: 11 November 2019
Accepted: 12 February 2020
First Online: 10 March 2020
Change Date: 25 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00262-021-02977-6
Compliance with ethical standards
:
: AL received honorarium from the companies BMS, MSD, Roche, Tesaro, Novartis, Astra Zeneca, Grünenthal. HS is employee of Immatics Biotechnologies GmbH. His work in conjunction with this article was solely performed as a member of the Universities’ Department of Immunology. SO holds a patent covering Cyclin A1-targeted T cell immunotherapy for cancer. The other authors declare no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (ethics committee 2 at Campus Virchow Charité Berlin Ref. No. EA 2/058/15) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
